Designs and manufactures ion implantation equipment. Provides high energy, high current, and medium current implanters. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
If every debt were paid off today, $331.9M would still be left in the vault — a solid cushion for hard times.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Debt is low and cash is strong; the finances stand solid.
Clearly below the class average.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Growth: Sales growth trails the sector average.
The stock trades 43% below its peak. The market has trimmed its expectations for the company.
There is $374.3M in the vault; even if every debt were paid off, $331.9M would remain.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 41/100.
The growth engine is running at low revs right now. Report-card grade: 41/100.
No clear buy-side message is coming from the executive floor.
On our five-subject report card, ACLS sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ACLS is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (41/100) says the stock isn’t cheap.